Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 10Active not recruiting 3Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

NIH 6OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Fallopian Tube Neoplasms 2Uterine Neoplasms 1Ovarian Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × adavosertib × Clear all
NCT02659241 2026-04-15

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
38 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
96 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
49 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡